<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84151</article-id><article-id pub-id-type="doi">10.7554/eLife.84151</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Cryo-EM reveals an unprecedented binding site for Na<sub>V</sub>1.7 inhibitors enabling rational design of potent hybrid inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-296718"><name><surname>Kschonsak</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296719"><name><surname>Jao</surname><given-names>Christine C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205358"><name><surname>Arthur</surname><given-names>Christopher P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296720"><name><surname>Rohou</surname><given-names>Alexis L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296721"><name><surname>Bergeron</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296722"><name><surname>Ortwine</surname><given-names>Daniel F</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296723"><name><surname>McKerrall</surname><given-names>Steven J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-111122"><name><surname>Hackos</surname><given-names>David H</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-80128"><name><surname>Deng</surname><given-names>Lunbin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296725"><name><surname>Chen</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-306043"><name><surname>Li</surname><given-names>Tianbo</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-313227"><name><surname>Dragovich</surname><given-names>Peter S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-80134"><name><surname>Volgraf</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296727"><name><surname>Wright</surname><given-names>Matthew R</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-296728"><name><surname>Payandeh</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-205359"><name><surname>Ciferri</surname><given-names>Claudio</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0804-2411</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-296717"><name><surname>Tellis</surname><given-names>John C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Structural Biology</institution>, <institution>Genentech, Inc</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Discovery Chemistry</institution>, <institution>Genentech, Inc</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Neuroscience</institution>, <institution>Genentech, Inc</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Biochemical and Cellular Pharmacology</institution>, <institution>Genentech, Inc</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Discovery Chemistry</institution>, <institution>Genentech, Inc</institution>, <addr-line><named-content content-type="city">South San Francsico</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Drug Metabolism and Pharmacokinetics</institution>, <institution>Genentech, Inc</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-110218"><name><surname>Sack</surname><given-names>Jon T</given-names></name><role>Reviewing editor</role><aff><institution>University of California, Davis</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>jpayandeh@exelixis.com</email> (JP);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>ciferri.claudio@gene.com</email> (CC);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>tellis.john@gene.com</email> (JT);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>03</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e84151</elocation-id><history><date date-type="received"><day>12</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>27</day><month>03</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Kschonsak et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Kschonsak et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84151-v1.pdf"/><abstract><p>The voltage-gated sodium (Na<sub>V</sub>) channel Na<sub>V</sub>1.7 has been identified as a potential novel analgesic target due to its involvement in human pain syndromes. However, clinically available Na<sub>V</sub> channel blocking drugs are not selective among the nine Na<sub>V</sub> channel subtypes, Na<sub>V</sub>1.1-Na<sub>V</sub>1.9. Moreover, the two currently known classes of Na<sub>V</sub>1.7 subtype-selective inhibitors (aryl- and acylsulfonamides) have undesirable characteristics that may limit their development. To this point understanding of the structure-activity relationships of the acylsulfonamide class of Na<sub>V</sub>1.7 inhibitors, exemplified by the clinical development candidate GDC-0310, has been based solely on a single co-crystal structure of an arylsulfonamide inhibitor bound to voltage-sensing domain 4 (VSD4). To advance inhibitor design targeting the Na<sub>V</sub>1.7 channel, we pursued high-resolution ligand-bound Na<sub>V</sub>1.7-VSD4 structures using cryogenic electron microscopy (cryo-EM). Here, we report that GDC-0310 engages the Na<sub>V</sub>1.7-VSD4 through an unexpected binding mode orthogonal to the arylsulfonamide inhibitor class binding pose, which identifies a previously unknown ligand binding site in Na<sub>V</sub> channels. This finding enabled the design of a novel hybrid inhibitor series that bridges the aryl- and acylsulfonamide binding pockets and allows for the generation of molecules with substantially differentiated structures and properties. Overall, our study highlights the power of cryo-EM methods to pursue challenging drug targets using iterative and high-resolution structure-guided inhibitor design This work also underscores an important role of the membrane bilayer in the optimization of selective Na<sub>V</sub> channel modulators targeting VSD4.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004328</institution-id><institution>Genentech</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kschonsak</surname><given-names>Marc</given-names></name><name><surname>Jao</surname><given-names>Christine C</given-names></name><name><surname>Arthur</surname><given-names>Christopher P</given-names></name><name><surname>Rohou</surname><given-names>Alexis L</given-names></name><name><surname>Bergeron</surname><given-names>Philippe</given-names></name><name><surname>Ortwine</surname><given-names>Daniel F</given-names></name><name><surname>McKerrall</surname><given-names>Steven J</given-names></name><name><surname>Hackos</surname><given-names>David H</given-names></name><name><surname>Deng</surname><given-names>Lunbin</given-names></name><name><surname>Chen</surname><given-names>Jun</given-names></name><name><surname>Li</surname><given-names>Tianbo</given-names></name><name><surname>Volgraf</surname><given-names>Matthew</given-names></name><name><surname>Wright</surname><given-names>Matthew R</given-names></name><name><surname>Payandeh</surname><given-names>Jian</given-names></name><name><surname>Ciferri</surname><given-names>Claudio</given-names></name><name><surname>Tellis</surname><given-names>John C</given-names></name></principal-award-recipient></award-group><funding-statement>N/A</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Tianbo Li, Genentech employee.</p></fn><fn fn-type="conflict" id="conf3"><p>Claudio Ciferri, MK, CCJ, ALR, DFO, DHH, LD, JC, PSD, MW, CC and JCT are Genentech employees. All authors declare no competing financial interest..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. The NaV1.7-NaVPas/GNE-3565 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0R and EMDB entry ID EMD-28778, respectively. The NaV1.7-NaVPas/GDC-0310 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0Q and EMDB entry ID EMD-28777, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 2 (GNE-9296) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0S and EMDB entry ID EMD-28779, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 4 (GNE-1305) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0P and EMDB entry ID EMD-28776, respectively.</p></sec><supplementary-material><ext-link xlink:href="elife-84151-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>